title: The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control.
abstract: Nephropathy progression is slowed and cardiovascular events reduced in patients with stage 3 or higher chronic kidney disease when blood pressure is controlled using combinations of renin-angiotensin system (RAS) blockers with dihydropyridine calcium channel blockers or diuretics. We discuss a trial comparing high-dose RAS blockade with lower-dose RAS blockade combined with a dihydropyridine calcium channel blocker. The primary outcome was cardiovascular events. The combination group had better blood pressure control and fewer total events.
authors.affiliation: American Society of Hypertension, Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medicine, Chicago, IL 60637, USA.
authors.forename: Alexandros
authors.initials: A
authors.lastname: Briasoulis
authors.forename: George L
authors.initials: GL
authors.lastname: Bakris
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000453:epidemiology*; D008297:Male; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000453:epidemiology*
chemical_list: D057911:Angiotensin Receptor Antagonists; D002121:Calcium Channel Blockers